Endometriosis is a painful and debilitating condition that affects one in every ten women. Despite being a common health issue, there are currently limited treatment…
NXI Therapeutics (formerly Nextimmune), the specialist biotech developing next generation immunosuppressive drugs for autoimmune diseases and organ transplantation, today announces that it has appointed Dr…
Anaveon, a clinical-stage immuno-oncology company, announced updated clinical data from the ongoing Phase I/II study of ANV419 in patients with solid tumors, as well as…
We are excited to welcome Phialogics as our newest portfolio company! Basel, Switzerland. 20 September 2022 - Phialogics is a preclinical stage company developing cell-type-specific…
One of our portfolio companies, Anaveon AG, announces FDA Safe to proceed letter for Investigational New Drug (IND) Application for its no-alpha IL-2 agonist, ANV419…
We are excited to welcome Onena Medicines as our newest portfolio company! Onena Medicines is a Swiss-Spanish biotech company emerging from the Chan Zuckerberg Biohub…
Engimmune is a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, founded in August 2021 by Dr. Rodrigo Vazquez-Lombardi, Prof Sai Reddy and Dr…
Cimeio therapeutics is a spin-off from the University of Basel. The scientific basis was born out of years of cutting-edge research by Professor Lukas Jeker–co-founder…
2022 started off on some good notes for BaseLaunch, with two new companies (one still in stealth) joining our portfolio and another one announcing the…